Much of the investor doubt surrounding Bristol-Myers Squibb’s $ 74 billion Celgene buyout centers on the multiple myeloma blockbuster Revlimid—namely, whether its remaining patents can stand up to legal challenges. But the companies just scored a win in that department. Thursday, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) decided not… Read More »
WASHINGTON (Reuters) – Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial. FILE PHOTO: An Amgen sign is seen at… Read More »
Amgen has been sweating potential copycats to its blockbuster calcium reducer Sensipar. But thanks to a patent deal with Teva, yet another challenger will have to wait until 2021 to sell its generic knockoff. This deal features a unique wrinkle, though. Teva had already launched its version, according to Bernstein analyst Ronny Gal, costing Amgen tens… Read More »
Scientists affiliated with Harvard and MIT have been battling with colleagues at University of California, Berkeley over who deserves patents for a revolutionary technology used in medical research. On Monday, the east coast scientists won their case in a federal appeals court. Health : NPR
Directions for use: • Press the wire plug firmly to the output port at the top of the unit; Connect the electrode pads to the electrode wire by inserting pins to the female pin electrodes; • Remove the protective film and place the electrode pads on the targeted area, making sure that both pads are… Read More »